CLNN Clene Inc.

Clene is revolutionizing the treatment of neurodegenerative disease with an innovative nanotherapeutic platform to generate first-in-class elemental nanomedicines designed to optimize neurorepair and health through energy-enhancing bioenergetic catalysis.

$1.16  -0.07 (-5.31%)
As of 03/22/2023 16:00:01 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/27/2018
Outstanding shares:  73,820,010
Average volume:  225,174
Market cap:   $88,584,012
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMW2FV3

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%